Skip to main content
Skip to footer
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
News Releases
Photo Corner
Video Corner
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
ACTRIMS Forum 2023
POSTER PRESENTATION
Thursday, February 23, 2023 – Saturday, February 25, 2023
Poster ACTRIMS Forum 2023
Next Post
Immunic’s Celiac Disease R&D Webcast
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study
Home – 2
About
Pipeline
News
Publications
Investors
Career
Contact
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Vidofludimus Calcium
IMU-856
IMU-381
IR Home
News Releases
Events and Presentations
Stock Informations
Financials and SEC Filings
Corporate Governance
IR Contact
Search
Search
